دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
Janet E Pope, Roy M Fleischmann
doi : 10.1136/ard-2022-223071
February 2023 - Volume 82 - 2
Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
Alvise Berti, Fabiola Atzeni, Lorenzo Dagna, Stefano Del Giacco, Giacomo Emmi, Carlo Salvarani, Augusto Vaglio
doi : 10.1136/ard-2022-223044
Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological agents specifically inhibiting the IL-5 pathway provided the opportunity to treat EGPA by targeting one of the crucial regulators of eosinophils, reducing the GC dose required to control the disease.
Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?
Ana Lorenzo-Vizcaya, David Alan Isenberg
doi : 10.1136/ard-2022-222839
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of unknown aetiology, characterised by the production of auto-antibodies and formation of immune complexes against self-antigens and complement activation. This inflammatory response can lead to tissue infiltration and eventually, to organ damage.
After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, Kim Lauper, Denis Mongin, Florenzo Iannone, Karel Pavelka, Dan C Nordström, Nevsun Inanc, Catalin Codreanu, Kimme L Hyrich, Denis Choquette, Anja Strangfeld, Burkhard F Leeb, Ziga Rotar, Ana Rodrigues, Eirik Klami Kristianslund, Tore K Kvien, Ori Elkayam, Galina Lukina, Sytske Anne Bergstra, Axel Finckh, Delphine Sophie Courvoisier
doi : 10.1136/ard-2022-222835
Objectives The expanded therapeutic arsenal in rheumatoid arthritis (RA) raises new clinical questions. The objective of this study is to compare the effectiveness of cycling Janus kinase inhibitors (JAKi) with switching to biologic disease-modifying antirheumatic drug (bDMARD) in patients with RA after failure to the first JAKi.
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Lea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian
doi : 10.1136/ard-2022-222824
Objectives To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib and baricitinib) versus adalimumab in a large real-world population of patients with rheumatoid arthritis.
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, Benedicte Delcoigne, Daniela Di Giuseppe, Johan Askling
doi : 10.1136/ard-2022-223050
Objective To assess and compare the incidence of venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi) or other biological disease modifying antirheumatic drugs (bDMARDs). For contextualisation, to assess VTE incidences in the Swedish general population and in the RA source population.
PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
Jiajie Tu, Weile Chen, Yilong Fang, Dafei Han, Yizhao Chen, Haifeng Jiang, Xuewen Tan, Zhen Xu, Xuming Wu, Huihui Wang, Xiangling Zhu, Wenming Hong, Zhenbao Li, Chen Zhu, Xinming Wang, Wei Wei
doi : 10.1136/ard-2022-222708
Objectives To uncover the function and underlying mechanism of an essential transcriptional factor, PU.1, in the development of rheumatoid arthritis (RA).
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
Robert B M Landewé, Denis Poddubnyy, Proton Rahman, Filip E Van den Bosch, Rebecca Bolce, Soyi Liu Leage, Jeffrey R Lisse, So Young Park, Lianne Gensler
doi : 10.1136/ard-2022-222731
Objectives To evaluate the recapture of response with open-label (OL) ixekizumab (IXE) retreatment at week 104 in patients with axial spondyloarthritis who flared after withdrawal of IXE therapy.
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
Michelle Petri, Helain Landy, Megan E B Clowse, Kim Gemzoe, Munther Khamashta, Milena Kurtinecz, Roger A Levy, Andrew Liu, Rebecca Marino, Paige Meizlik, Jeanne M Pimenta, Kelsey Sumner, Hugh Tilson, Mary Beth Connolly, Keele Wurst, Julia Harris, Holly Quasny, Patricia Juliao, David A Roth
doi : 10.1136/ard-2022-222505
Objective Describe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab.
3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
Ming Zhao, Delong Feng, Longyuan Hu, Lin Liu, Jiali Wu, Zhi Hu, Haojun Long, Qiqi Kuang, Lianlian Ouyang, Qianjin Lu
doi : 10.1136/ard-2022-222653
Objectives Three-dimensional (3D) genome alterations can dysregulate gene expression by rewiring physical interactions within chromosomes in a tissue-specific or cell-specific manner and lead to diseases. We aimed to elucidate the 3D genome structure and its role in gene expression networks dysregulated in systemic lupus erythematosus (SLE).
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies
Danlei Zhou, Emily H King, Simon Rothwell, Olga Krystufkova, Antonella Notarnicola, Samantha Coss, Rabheh Abdul-Aziz, Katherine E Miller, Amanda Dang, G Richard Yu, Joanne Drew, Emeli Lundström, Lauren M Pachman, Gulnara Mamyrova, Rodolfo V Curiel, Boel De Paepe, Jan L De Bleecker, Antony Payton, William Ollier, Terrance P O'Hanlon, Ira N Targoff, Willy A Flegel, Vidya Sivaraman, Edward Oberle, Shoghik Akoghlanian, Kyla Driest, Charles H Spencer, Yee Ling Wu, Haikady N Nagaraja, Stacy P Ardoin, Hector Chinoy, Lisa G Rider, Frederick W Miller, Ingrid E Lundberg, Leonid Padyukov, Jiřà Vencovský, Janine A Lamb, Chack-Yung Yu
doi : 10.1136/ard-2022-222935
Background Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterised by myositis-related autoantibodies plus infiltration of leucocytes into muscles and/or the skin, leading to the destruction of blood vessels and muscle fibres, chronic weakness and fatigue. While complement-mediated destruction of capillary endothelia is implicated in paediatric and adult dermatomyositis, the complex diversity of complement C4 in IIM pathology was unknown.
Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies
Yuji Hosono, Brandon Sie, Iago Pinal-Fernandez, Katherine Pak, Christopher A Mecoli, Maria Casal-Dominguez, Blake M Warner, Mariana J Kaplan, Jemima Albayda, Sonye Danoff, Thomas E Lloyd, Julie J Paik, Eleni Tiniakou, Rohit Aggarwal, Chester V Oddis, Siamak Moghadam-Kia, Carmelo Carmona-Rivera, Jose César Milisenda, Josep Maria Grau-Junyent, Albert Selva-O'Callaghan, Lisa Christopher-Stine, H Benjamin Larman, Andrew Lee Mammen
doi : 10.1136/ard-2022-222441
Objectives In dermatomyositis (DM), autoantibodies are associated with unique clinical phenotypes. For example, anti-TIF1γ autoantibodies are associated with an increased risk of cancer. The purpose of this study was to discover novel DM autoantibodies.
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission
Gabriele Gamerith, Finn Mildner, Peter A Merkel, Kristina Harris, Laura Cooney, Noha Lim, Robert Spiera, Philip Seo, Carol A Langford, Gary S Hoffman, E William St Clair, Fernando C Fervenza, Paul Monach, Steven R Ytterberg, Duvuru Geetha, Arno Amann, Dominik Wolf, Ulrich Specks, John H Stone, Andreas Kronbichler
doi : 10.1136/ard-2022-222479
Objectives We investigated whether soluble immune checkpoints (sICPs) predict treatment resistance, relapse and infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).
Targeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis
Hiroki Ohzono, Yiwen Hu, Keita Nagira, Haruhisa Kanaya, Naoki Okubo, Merissa Olmer, Masafumi Gotoh, Ichiro Kurakazu, Yukio Akasaki, Manabu Kawata, Emily Chen, Alan C Chu, Kristen A Johnson, Martin K Lotz
doi : 10.1136/ard-2021-221269
Objectives Osteoarthritis (OA) features ageing-related defects in cellular homeostasis mechanisms in articular cartilage. These defects are associated with suppression of forkhead box O (FoxO) transcription factors. FoxO1 or FoxO3 deficient mice show early onset OA while FoxO1 protects against oxidative stress in chondrocytes and promotes expression of autophagy genes and the essential joint lubricant proteoglycan 4 (PRG4). The objective of this study was to identify small molecules that can increase FoxO1 expression.
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Alexander J Knights, Easton C Farrell, Olivia M Ellis, Lindsey Lammlin, Lucas M Junginger, Phillip M Rzeczycki, Rachel F Bergman, Rida Pervez, Monique Cruz, Eleanor Knight, Dennis Farmer, Alexa A Samani, Chia-Lung Wu, Kurt D Hankenson, Tristan Maerz
doi : 10.1136/ard-2022-222773
Objectives Synovium is acutely affected following joint trauma and contributes to post-traumatic osteoarthritis (PTOA) progression. Little is known about discrete cell types and molecular mechanisms in PTOA synovium. We aimed to describe synovial cell populations and their dynamics in PTOA, with a focus on fibroblasts. We also sought to define mechanisms of synovial Wnt/β-catenin signalling, given its emerging importance in arthritis.
Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study
Sanjana Tarannum, Jessica Widdifield, C Fangyun Wu, Sindhu R Johnson, Paula Rochon, Lihi Eder
doi : 10.1136/ard-2022-222779
Objectives Our aim was to compare patterns of musculoskeletal-related healthcare utilisation between male and female patients before and after the diagnosis of inflammatory arthritis (IA).
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Göschl, Nikolaus Hommer, Margareta Mayer, Philipp Hofer, Thomas Hummel, Thomas Deimel, Irina Geßl, Antonia Puchner, Andreas Kerschbaumer, Renate Thalhammer, Alessandra Handisurya, Renate Kain, Stefan Winkler, Josef S Smolen, Karin Stiasny, Thomas Perkmann, Helmuth Haslacher, Judith H Aberle, Daniel Aletaha, Leonhard X Heinz, Daniela Sieghart, Michael Bonelli
doi : 10.1136/ard-2022-222682
Objectives A third COVID-19 vaccination is recommended for immunosuppressed patients. However, data on immunogenicity and safety of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) are sparse and therefore addressed within this clinical trial.
Tumorous calcinosis of the atlantoaxial joint: the helmeted dens syndrome
Frank Verhoeven, Mickaël Chouk, Clémentine Delcourt, Clément Prati, Daniel Wendling
doi : 10.1136/ard-2022-223020
Correspondence on ‘prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’
Jiyuan Shi, Ya Gao, Lili Zhang, Yang Zhao, Jianguo Xu, Jinhui Tian
Response to ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Shi et al
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey
Cloé Comarmond, Mathilde Leclercq, Gaëlle Leroux, Cindy Marques, Alexandre Le Joncour, Fanny Domont, Céline Hatte, Ségolène Toquet-Bouedec, Perrine Guillaume-Jugnot, Anne-Claire Desbois, Mathieu Vautier, Aude Rigolet, Yves Allenbach, Olivier Benveniste, David Saadoun, Patrice Cacoub
Response to: ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’ by Comarmond et al
Alessandro Tomelleri, Silvia Sartorelli, Elena Marina Baldissera, Lorenzo Dagna, Corrado Campochiaro
Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
Adeline Ruyssen-Witrand, Martin Soubrier, André Basch, Marie-Elise Truchetet, Raphaèle Seror
Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et al
Adrian Ciurea, Axel Finckh
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Enrique Calvo-Aranda, Irene Cañamares-Orbis, Marta Novella-Navarro, Alvaro Martinez-Alcala, Maria del Carmen Ortega de la O, Ismael Escobar-Rodriguez, Fernando Manuel Sanchez-Aranda
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Calvo-Aranda et al
Sofia Ramiro, Rémy Mostard, Robert BM Landewé
Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic—World Scleroderma Foundation preliminary advice for patient management
Elena Snarskaya, Kseniia Vasileva
Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management’’ by Snarskaya and Vasileva
Cosimo Bruni, Marco Matucci-Cerinic
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
Maurizio Benucci, Arianna Damiani, Gianfranco Giannasi, Francesca Li Gobbi, Luca Quartuccio, Valentina Grossi, Maria Infantino, Mariangela Manfredi
Impact of lockdown on rheumatology outpatient care in the age of COVID-19
Benjamin Sachdev Manjit Singh, Seow Lin Chuah, Yaw Kiet Cheong, Sharifah Aishah Wan, Cheng Lay Teh
Correspondence on ‘EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups’
Irfan Mohammad, Phani Kumar Devarasetti, Liza Rajasekhar
Response to: ‘Correspondence on ‘EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups’’ by Irfan et al
Ingrid E Lundberg, Frederick W Miller, Lisa G Rider, Victoria P Werth, Anna Tjärnlund, Matteo Bottai
Correspondence on ‘Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia’
Gerasimos Evangelatos, George E Fragoulis, Alexios Iliopoulos
Response to: ‘Correspondence on ‘Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia’’ by Evangelatos et al
Kornelis SM van der Geest, Bhaskar Dasgupta
Correspondence on ‘EULAR recommendations for a core data set for pregnancy registries in rheumatology
Diederik De Cock, Isaline Soenen, Delphine Bertrand, Sofia Pazmino, Veerle Stouten, Rene Westhovens, Patrick Verschueren
Response to: ‘Correspondence on ‘EULAR recommendations for a core data set for pregnancy registries in rheumatology� by De Cock et al
Yvette Meissner, Rebecca Fischer-Betz, Angela Zink, Anja Strangfeld
Correspondence on ‘Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017’
Ping-Hao Chiang, Po-Chung Ju, Yun-Chi Chiang, James Cheng-Chung Wei
Response to: ‘Correspondence on ‘Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the Global Burden of Disease study 2017’ by Chiang et al
Ziyi Jin, Jinkou Zhao, Lingyun Sun
Correspondence on ‘Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease
Jiali Chen, Tian Liu, Jing He, Yudong Liu
Response to: ‘Correspondence on ‘Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease’’ by Chen et al
Alexandre Le Joncour, David Saadoun, Yacine Boulaftali
Correspondence on ‘Prevotella copri in individuals at risk for rheumatoid arthritis’
Tianyue Sun, Jing Ni
Response to: ‘Correspondence on ‘Prevotella copri in individuals at risk for rheumatoid arthritis’’ by Sun and Ni
Benoît Thomas P Gilbert, Axel Finckh, Deshire Alpizar Rodriguez
Correction: 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis
Correction: Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis
